Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads by Date

Must reads for theWeek ending July 1, 2018

Lenalidomide-refractory MM responds to triple therapy, Chari A et al. J Clin Oncol 36, 2018 (suppl, abstr 8002).

Ibrutinib and venetoclax for relapsed CLL, Niemann C et al. European Society of Hematology Annual Congress 2018. Abstract PF346.

Relapsed CLL responds to rapid venetoclax dose-escalation, Awan F et al. European Hematology Association 2018 Annual Congress. Abstract PF357

Doubling of deaths in hospice care over 5-year span, Teno JM et al. JAMA. 2018 Jun 25. doi: 10.1001/jama.2018.8981.

Patient-specific risk factors for BCC, SCC examined in study, Scott J et al. Presentation at American College of Mohs Surgery, May 2018.

More must reads

Must reads for theWeek ending June 24, 2018

Policy statement on access to opioid medications, Statement on Opioid Use in Patients with Hematologic Diseases and Disorders, American Society of Hematology

FDA approves Mircera for dialysis-related anemia in pediatric patients, FDA approved-drug notice, June 7, 2018; Mircena label ([email protected])

FDA approves pembrolizumab for relapsed/refractory PMBCL, FDA Press Announcement, June 15, 2018; Keytruda Prescribing Information ([email protected])

Poor adherence to DOAC therapy requires attention, Lakkireddy D et al. Heart Rhythm 2018, Abstract B-LBCT02-03.

Red cell tranfusion may increase risk of postsurgical VTE, Goel R et al. JAMA Surg. 2018 Jun 13. doi: 10.1001/jamasurg.2018.1565

More must reads

Must reads for theWeek ending June 17, 2018

Oncologists file suit challenging Part B payment reductions, May 30 letter to HHS Secretary Alex Azar alerting him to the legal action, which was filed on May 31.

One-third of IDH1-mutated AML cases have complete response to ivosidenib , Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.

Ruxolitinib add-on boosted myeloma response, Berenson JR, et al. J Clin Oncol 36, 2018, suppl. (ASCO 2018, annual meeting of the American Society of Clinical Oncology); abstr 8005.

Getting to MRD in ALL boosted survival, Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.

CLL gets to MRD with combo therapy, Wierda WG et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7502.

More must reads

Must reads for theWeek ending June 3, 2018

Skin side effects of therapies for hematologic cancers, Phillips et al. J Am Acad Dermatol. 2018;78:1102-9.

Sepsis-related coagulopathy and in-hospital death risk, Lyons PG et al. Crit Care Med. 2018 May;46(5):73642.

Refractory myeloma may respond to ruxolitinib add-on, Berenson JR, et al. J Clin Oncol 36, 2018 (suppl; abstr 8005).

New option for IDH1-mutated AML, Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl; abstr 7000).

Pediatric cancers rising, Siegel DA et al. ASPHO 2018, Abstract 605.

More must reads

Must reads for theWeek ending June 3, 2018

Skin side effects of therapies for hematologic cancers, Phillips et al. J Am Acad Dermatol. 2018;78:1102-9.

Sepsis-related coagulopathy and in-hospital death risk, Lyons PG et al. Crit Care Med. 2018 May;46(5):73642.

Refractory myeloma may respond to ruxolitinib add-on, Berenson JR, et al. J Clin Oncol 36, 2018 (suppl; abstr 8005).

New option for IDH1-mutated AML, Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl; abstr 7000).

Pediatric cancers rising, Siegel DA et al. ASPHO 2018, Abstract 605.

More must reads

Pages